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BACKGROUND: Tumor necrosis factor (TNF)-α, an important primary pro-inflammatory cytokine, has a crucial role in the pathogenesis of atherosclerosis. 
Since the pathophysiological mechanism of coronary slow 
flow (CSF) is not fully understood, we investigated the 
level of TNF-α in coronary artery disease (CAD), CSF and 
healthy subjects. 
METHODS: This study was conducted in cross-sectional 
design involving 16 CAD, 18 CSF and 18 healthy 
subjects. Coronary angiography was recorded at the 
left anterior  oblique,  cranial,  right  anterior  oblique, 
caudal, and horizontal positions. The flow in coronary 
arteries of the subjects were assessed using Thrombolysis 
in the Myocardial Infarction (TIMI) frame count method. 
Peripheral blood-derived serum was collected and level of 
TNF-α was determined by  using  highly  sensitive  enzyme-
linked immunosorbent assay (ELISA).
RESULTS: No significant difference in level of TNF-α in 
CAD, CSF and healthy subjects (2.72±2.64 pg/mL, 1.88±0.8 
pg/mL, 1.64±0.35 pg/mL, respectively) (p=0.087). In 
addition, there was no correlation between the concentration 
of TNF-α and TIMI frame count (r<0.2, p>0.05). 
CONCLUSION: There was no significant difference of 
TNF-α level in CAD, CSF and healthy subjects. In addition, 
there was no correlation between the TNF-α level with TIMI 
frame count as well. Nevertheless, further clinical studies 
with more subjects are needed.
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Abstract
Introduction
WHO has reported the cardiovascular disease (CVD) is 
progressively becoming the principle causes of death all 
over the world since 2008. The WHO health report has also 
estimated the mortality caused by CVD will rise from 17.1 
million in 2004 to 23.4 million in 2030.(1) Atherosclerosis 
occurs due to the outcome of inflammatory and fibro-
proliferative events, by which some factors happen in 
response to the localization of atherogenic lipoproteins 
on the intima layer of the blood vessel wall. A number of 
studies have found that signs of systemic inflammation can 
become powerful future predictors of cardiovascular events 
in healthy, low risk individuals without overt cardiovascular 
disease and those with coronary artery disease (CAD). 
Increase in concentration of inflammatory mediators can 
foresee the adverse cardiovascular events.(2,3)
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 An important primary pro-inflammatory cytokine that 
has  a  crucial  role  in  the  pathogenesis  of  atherosclerosis 
is the  tumor  necrosis  factor  (TNF)-α.  TNF-α  is 
produced  by several  types of cells especially macrophages 
and is involved in systemic inflammatory conditions. 
This cytokine affects the myocardium in some diseases 
such as myocarditis, ischemic heart disease and cardiac 
dysfunction.(4) Previous studies suggested that TNF-α 
levels was correlated with coronary atherosclerosis.(5) 
Although elevated  level of TNF-α in CAD is known, only 
a few data is available for the level of TNF-α in coronary 
slow flow (CSF). Hence, the present study was conducted to 
investigate whether the difference of TNF-α level in CAD, 
CSF and healthy subjects.
Methods
Study Subject
The protocol of this cross-sectional study was approved 
by the Ethical Review Committee, Faculty of Medicine, 
Universitas Syiah Kuala, Banda Aceh, Indonesia (No. 
205/KE/FK/2013). Prior to the study, all subjects have 
signed the written informed consent. The study was 
conducted from November 2013 to February 2014 in the 
Division of Cardiology, Department of Internal Medicine, 
Faculty of Medicine, Universitas Syiah Kuala and Cardiac 
Catheterization Laboratory at dr. Zainoel Abidin Regional 
General Hospital, Banda Aceh. Subjects aged >26 years 
were consecutively recruited. Subjects who had clinical 
symptoms of chest pain typical of angina and undertook 
coronary angiography, were then divided into groups of 
CAD and CSF subjects based on the results of angiography. 
Meanwhile, subjects who didn’t have chest discomfort 
confirmed by electrocardiography and didn’t undertake 
coronary angiography, were grouped as healthy subjects. 
Subjects with total stenosis coronary artery and coronary 
artery  bypass  graft  were  excluded.  Subjects  with 
significant comorbidities, including hypertension, diabetes 
mellitus,  the use of anti-inflammatory drugs other than 
aspirin, renal or hepatic dysfunction,  body mass index 
(BMI) >22.9 kg/m2 or <18.5 kg/m2, smoker, and alcohol 
consumption, were excluded as healthy subjects.
Coronary Angiography and Thrombolysis in the 
Myocardial Infarction (TIMI)
The standard Judkins technique was employed to perform 
the coronary angiography. The coronary angiography 
was recorded at the left anterior oblique, cranial, right 
anterior oblique, caudal, and horizontal positions. These 
examinations were done by two cardiologists who did not 
have any information on the clinical characteristics of the 
subjetcs. 
 Furthermore, the flow in coronary arteries of the 
subjects were assessed using TIMI frame count method.(6)
The differences between the first and last frames in the 
TIMI frame count were calculated. The cut-off values from 
the length for normal visualization of coronary arteries 
were 36.2±2.6 frames for Left Anterior Descending Artery 
(LAD), 22.2±4.1 frames for Left Circumflex Artery (LCx), 
and 20.4±3 frames for Right Coronary Artery (RCA). 
The corrected cut-off value for LAD coronary artery was 
21.1±1.5 frames. The mean TIMI frame count for each 
subject was calculated by dividing the sum of the TIMI 
frame count of LAD, LCx and RCA by 3.
Sample Collection, Preparation and Measurement
Five mL peripheral blood sample of each subject was 
obtained from the antecubital vein and collected in non-
heparinized glass tube. The tube was put on ice immediately 
after collection for 30-45 min. After that, the tube was 
centrifuged at 3000 rpm for 15 min. Serum was collected 
and stored at -20°C freezer.  
 For the concentration of TNF-α measurement, serum 
was thawed and immediately processed with Human 
TNF-α Quantikine HS enzyme-linked immunosorbent 
assay (ELISA) kit (R&D Systems, Minneapolis, USA). 
Other blood tests for hemoglobin, hematocrit, white blood 
cell, platelet, erythrocyte sedimentation rate (ESR), total 
cholesterol, low-density lipoprotein (LDL) cholesterol, 
high-density lipoprotein (HDL) cholesterol, triglyceride, 
urea, creatinine, urid acid, fasting glucose and 2-hour post 
prandial glucose, were perfomed using standard methods in 
dr. Zainoel Abidin Hospital.
Statistical Analysis
Conformity to normal distribution of the continuous 
variables was examined with the Shapiro-Wilk test. 
Parametric or non-parametric tests were performed based 
on the data distribution and number of groups. Conferring 
to data distribution, post hoc comparisons were conducted 
with the suitable test. The paired-sample t-test was used 
to compare the dependent groups and the Pearson’s 
or Spearman correlation test was used to evaluate the 
correlation between variables. The p<0.05 was considered 
as statistically significant.
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Results
Fifty-two subjects were included in the study, 16 with CAD, 
18 only CSF and 18 healthy subjects. Demographic and 
clinical characteristics of the subjects are summarized in 
Table 1. There were significant differences in terms of age, 
BMI, and SBP of CAD, CSF and healthy subjects. CAD 
subjects had the highest BMI and SBP levels. Based on 
laboratory results, platelet, triglyceride, urea, creatinine, uric 
acid and 2-hour post prandial glucose were also significantly 
different. CAD subjects had the highest creatinine, uric acid 
and 2-hour post prandial glucose levels. CSF subjects had 
the highest triglyceride and urea levels. Healthy subjects 
had the highest platelet count.
 TIMI Frame Counts of CAD and CSF subjects are 
shown in Table 2. There was not any significant difference 
Variable CAD (n=16) CSF (n=18) Healthy (n=18) p- value
Age (years) 58.13±8.24 53.39±10.08 44.22±8.59 <0.001a,*
Male gender (n (%)) 10 (62.50%) 11 (61.11%) 6 (33.33%) 0.148b
BMI (kg/m2) 25.13 (21.87-35.15) 24.80 (18.73-34.66) 21.38 (19.26-22.22) <0.001c,*
SBP (mmHg) 144.38±23.08 131.67±11.50 114.44±7.84 <0.001a,*
DBP (mmHg) 83.13±10.14 83.06±10.73 78.33±3.83 0.186a
Hemoglobin (g/dL) 13.68±1.91 13.60±2.56 12.67±1.24 0.257a
Hematocrit (%) 38.59±6.28 39.10±7.08 37.90±2.75 0.817a
Leukocyte (cells/µL) 8,115 (3,800-25,510) 7,350 (5,100-17,250) 7,905 (3,880-13,110) 0.695b
Platelet (103/µL) 258.5 (150-290) 242 (171-423) 311 (229-434) 0.005b
ESR (mm/hour) 21.94±16.13 22 (2-130) 16 (1-45) 0.172b
Total Cholesterol (mg/dL) 197.38±36.03 210.67±65.92 183.22±31.44 0.231a
LDL cholesterol (mg/dL) 116.81±32.35 135.61±55.15 116.67±28.13 0.290a
HDL cholesterol (mg/dL) 44.94±11.89 40.11±14.93 47.50±8.95 0.192a
Triglyceride (mg/dL) 111 (54-416) 125.50 (35-222) 74.50 (38-194) 0.019b
Urea (mg/dL) 25.50 (10-75) 29.50 (14-74) 21 (15-33) 0.026b
Creatinine ( mg/dL) 1.06 (0.60-2.43) 1.01 (0.60-1.80) 0.73 (0.56-1.18) 0.007b
Urid Acid (mg/dL) 6.87±2.63 6.46±1.94 5.01±1.32 0.022a
Fasting glucose (mg/dL) 99.50 (74-141) 99 (69-250) 89.50 (79-111) 0.250b
2-hour post prandial glucose (mg/dL) 143 (84-307) 140 (86-561) 102.50 (91-152) 0.001b
Table 1. Demographic and clinical characteristics of CAD, CSF and healthy subjects.
Data were presented as mean±SD, median (minimum-maximum) or n (%). BMI: Body Mass Index; SBP: Systolic Blood Pressure; DBP: 
Diastolic Blood Pressure; ESR: Erythrocyte Sedimentation Rate; LDL: Low-density Lipoprotein; HDL, High-density Lipoprotein. aOne-
way analysis of variance (ANOVA) test with Dunnett's post-hoc; bChi square test; cKruskall-Wallis test with Mann-Whitney post-hoc; 
*significance at p<0.001.
of TIMI frame count for RCA, LCx, LAD, cTFC LAD 
and cTFC in both groups. The most common of target 
vessel in CSF subjects was RCA (94.44%) of all three 
coronary arteries. The number of RCA in CSF subjects was 
significantly different compared to the number of CSF in 
CAD subjects (p<0.001).
 ELISA results showed that TNF-α levels of CAD was 
the highest. However, the TNF-α levels of CAD, CSF and 
healthy subjects were not significantly different (Table 3). 
The TNF-α levels were not significantly correlated with 
TIMI frame count (Table 4).
Discussion
CSF has been demonstrated to be more common in males, 
smokers, and individuals with hyperlipidemia, metabolic 
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Table 2. TIMI frame counts of CAD and CSF subjects.
Variable CAD (n=16) CSF (n=18)  p- value
RCA (frame counts) 28.07±8.82 26.83±3.87 0.486d
LCx (frame counts) 34.4±10.34 28.37±2.76 0.003d
LAD (frame counts) 47.27±10.11 42.37±7.77 0.040d
cTFC LAD (frame counts) 27.80±5.96 24.67±4.81 0.029d
cTFC (frame counts) 30.13±7.94 26.83±3.55 0.042d
Target vessel (n (%))
-   RCA 4 (25%) 17 (94.44%) <0.001b,*
-   LCx 4 (25%) 15 (83.33%) 0.001b
-   LAD 13 (81.25%) 16 (88.89%) 0.648b
Data were presented as mean±SD or n (%). RCA: Right Coronary Artery; LCx: Left 
Circumflex Artery; LAD: Left Anterior Descending Artery; cTFC: Corrected Thrombolysis 







CAD (n= 16) 2.72 ± 2.64 1.87 (1.09-12.16) 1.70-2.56
CSF (n=18) 1.88 ± 0.87 1.64 (1.10-4.26) 1.22-2.12
Healthy subjects (n=18) 1.64 ± 0.35 1.61 (1.03-2.14) 1.34-1.93
0.087e
Table 3. Comparison of TNF-α level in CAD, CSF and healthy subjects.
eKruskal-Wallis Test.
syndrome, or obesity.(7)  In our study, age, BMI dan SBP 
were significantly different. CSF subjects were younger than 
CAD subjects. Regarding BMI, our current results were in 
accordance with previous report. BMI was suggested as 
an independent predictor of CSF in the North American 
population.(8)
 Atherosclerosis, the main cause of CAD, is an 
inflammatory process involving vascular wall cells along 
with activation of inflammation markers.(9) Vessel wall 
inflammation is the key trait in the initiation, progression, 
and terminal steps of atherosclerosis. It further leads to 
plaque rupture and thrombosis. A number of systemic 
markers of inflammation have also been examined and 
associated to calculate future cardiovascular events and 
to identify patients at risk.(3,10) They include interleukin 
(IL)-1, IL-6, IL-8, TNF-α, anti-inflammatory cytokines IL-1 
receptor antagonist, and IL-10.(5,11) TNF-α is a potent pro-
inflammatory cytokine discharged by most cell types with 
pleiotropic effects.  Many studies reported the correlation 
of TNF-α and cardiovascular disease.(12,13) Carotid 
atherosclerosis has also been correlated to TNF receptor 
levels, however, it is not associated to serum TNF-α levels.
(14)  A  recent  study  did  not  find  a  correlation between 
atherosclerotic burden and IL-6 or TNF-α.(15) Another 
study have shown there was a significant correlation 
between TNF-α and the severity of CAD.(3) In our study, 
we found no significant difference in serum level of TNF-α 
between the CAD, CSF and healthy subjects. 
  Our current results showed that the most common of 
target vessel in CSF group was RCA. These results were 
in in accordance with previous report on angiographic 
characteristics in patient with CSF. The RCA was found 
as the predominant vessel involved in CSF.(16) However, 
another study showed the most common  artery involved 
was LAD, followed by LCX and RCA.(17) 
 There were many studies indicating endothelial 
function is impaired in patients with CSF. TIMI frame 
count was correlated with endothelial dysfunction.(18) 
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Variable 95% Confidence Interval p- valuef
RCA -0.150 (-0.464-0.198) 0.397
LCx -0.178 (-0.486-0.17) 0.314
LAD -0.071 (-0.399-0.273) 0.689
cTFC LAD -0.071 (-0.399-0.273) 0.689
cTFC -0.214 (-0.514-0.133) 0.224
Table 4. Correlation between TNF-α level and TIMI frame 
count.
fSpearman’s correlation test.
In our study, there was no correlation between the TNF-α 
level with TIMI frame count. The results showed inverse 
correlation between the TNF-α level and TIMI frame count. 
In another study, plasma nitric oxide (NO) levels were found 
to be lower in patients with SCF than in healthy subjects, so 
that NO level were negatively correlated with TIMI frame 
count.(19) 
Conclusion
In conclusion, the results of the present study show no 
significant difference of TNF-α level in CAD, CSF and 
healthy subjects. In addition, there was no correlation 
between the TNF-α level with TIMI frame count as well. 
Nevertheless, further clinical studies with more subjects are 
needed.
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